A proprietary transdermal delivery system utilizing sufentanil, a potent opioid, for the treatment of chronic pain.
View complete product pipeline
March 30, 2015DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study
March 02, 2015DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development
March 02, 2015DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs
February 23, 2015DURECT Corporation Invites You to Join its Fourth Quarter 2014 Earnings Conference Call